Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

y not warrant further development of this compound for the treatment of chronic hepatitis B and completing our clinical studies may take longer or cost more than expected. In addition, feedback from regulatory authorities or results from clinical trials might require modifications or delays in later stage clinical trials or additional trials to be performed. Further, the FDA and other regulatory authorities may not approve tenofovir DF for the treatment of chronic hepatitis B, and marketing approval, if granted, may have significant limitations on its use and physicians and may not see advantages of tenofovir DF over other treatment options and may therefore be reluctant to prescribe tenofovir DF for chronic hepatitis B. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Report on Form 10-Q for the first quarter of 2007, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Hepsera and Viread are registered trademarks of Gilead Sciences, Inc.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.


CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
James Loduca, 650-522-5908 (Media)
www.gilead.com

SOURCE: Gilead Sciences, Inc.



'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:8/31/2015)... Premune and Innovet ... licensing agreement for Redonyl ® Ultra. The product, ... veterinary dermatology market, is a nutritional supplement based on ... in dogs and cats. Redonyl ® Ultra is ... has been received positively in the country by veterinarians ...
(Date:8/31/2015)... PLEASANTON, Calif. , Aug. 31, 2015  QT Vascular ... "QT Vascular", and together with its subsidiaries, the ... assembly and distribution of advanced therapeutic solutions for ... today the final results of the below-the-knee ("BTK") ... Registry ("BAR") which were presented on August 15, ...
(Date:8/31/2015)... Aug. 31, 2015   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell ... cryopreservation freeze media and a related ... for smart shippers ("BioLife" or the ... an advanced biopharmaceutical company focused on developing and ...
Breaking Medicine Technology:Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
... BOSTON, April 4, 2011 PAREXEL International Corporation (NASDAQ: ... financial results on Monday, May 2, 2011 after the close ... PAREXEL,s website at www.PAREXEL.com and on the PR ... host a conference call and live webcast at 10:00 a.m. ...
... CITY, Calif., April 4, 2011 Sofie Biosciences, a ... launch of GENISYS4, their new benchtop small animal PET ... Cancer Research Annual Meeting, this compact, preclinical multimodality PET ... and measure the biology of disease and therapeutic response ...
Cached Medicine Technology:PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call 2Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology 2
(Date:9/1/2015)... ... 01, 2015 , ... Éminence Organic Skin Care is adding ... Peels. This revolutionary collection of natural peel solutions complements the existing routine for ... Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented peels deliver ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Dr. Trace Curry ... JourneyLite of Cincinnati. In the last month the FDA has approved two intra-gastric ... ™. These procedures represent the first incisionless, reversible, weight loss procedures available to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... archiving solution integrated with Alfresco‘s enterprise content management system. PRO Archiver for ... millions of dollars in printing costs by digitizing vast amounts of customer ...
(Date:9/1/2015)... Pasadena, California (PRWEB) , ... September 01, 2015 ... ... Anna Arrowsmith interviewed dating men and pick-up artists about their experiences of female ... alongside men’s bodily concerns, including penis issues, as well as their relationships with ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Anthony J. ... the Super Lawyers 2015 for his third consecutive year in a row. Through ... accomplishments of helping people. , Born in Niagara Falls, New York, Tantillo is a ...
Breaking Medicine News(10 mins):Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2
... test is all it could take to tell if you ... team of international scientists have discovered more than 10 types ... of a person who recently suffered a stroke or heart ... international collaboration led by Nanyang Technological University (NTU),s lead scientist, ...
... Virginia G. Piper Cancer Center Clinical Trials are the first ... determine the safety, tolerability and preliminary activity of an investigational ... form of lung cancer, as well as other forms of ... patient on the study was administered the first dose of ...
... in infant death are significantly more likely to have ... September) in BJOG: An International Journal of Obstetrics ... rates of stillbirth in subsequent pregnancy, the study by ... the University of Rochester found. Infant mortality ...
... News) -- People who are depressed are at greater risk ... researchers pointed out that the findings could have a significant ... of death and permanent disability. Researchers analyzed 28 previous ... 8,478 stroke cases. The investigators found that depression was associated ...
... Scientists proposing to develop vaccines against methamphetamine and nicotine ... for Innovative Medication Development Research. The two scientists, ... and Dr. Peter Burkhard, of the University of Connecticut, ... years to support their research, according to the National ...
... , TUESDAY, Sept. 20 (HealthDay News) -- Black women who develop ... second cancer in the other breast, and those who are diagnosed ... cancer of a more aggressive form, new research indicates. ... to be more aggressive, more likely to be estrogen-receptor negative and ...
Cached Medicine News:Health News:Novel research set to pinpoint risk of heart attacks and strokes 2Health News:Novel research set to pinpoint risk of heart attacks and strokes 3Health News:TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer 2Health News:Infant mortality linked to subsequent risk of stillbirth finds new US study 2Health News:Infant mortality linked to subsequent risk of stillbirth finds new US study 3Health News:Depression Tied to Higher Risk for Stroke 2Health News:NIDA Avant-Garde-Medications Development Award winners announced 2Health News:Higher Risk of Second Breast Cancer Seen in Black Women 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: